Sun Pharmaceutical Industries Limited — Q1 FY27 earnings call

Call held 31 Jul 2026

Management summary

Sun Pharmaceutical reported a strong Q1 FY27 with consolidated sales up 10.1% YoY, driven by robust growth in India and Global Innovative Medicines. Gross margins improved to 80.5% due to a favorable product mix. However, the US business saw a 9.7% decline, mainly from Lenalidomide erosion, and emerging markets growth slowed due to external factors. The Organon acquisition is on track for Q4 FY27, incurring initial exceptional costs, and the effective tax rate increased.

Highlights

  • Consolidated sales grew 10.1% YoY to ₹15,183.6 crores, driven by strong performance in India and Global Innovative Medicines.

  • India formulations sales recorded a robust 16% growth to ₹5,474.9 crores, accounting for 36.1% of total consolidated sales.

  • Global Innovative Medicines sales increased by 12.8% to USD351 million, contributing 21.9% of total sales.

  • Gross margin improved to 80.5% due to a better product mix, despite the loss of Lenalidomide sales.

  • The company maintains a strong balance sheet with a net cash position of $3.4 billion.

Concerns

  • US business sales declined by 9.7% to USD427 million, primarily due to Lenalidomide erosion and additional competition in certain generic products.

  • EBITDA margins were slightly lower at 28.9% compared to Q1 FY26, which had a benefit from Lenalidomide sales.

  • Effective tax rate increased to 27.8% from 24.3% in Q1 FY26, as the benefit from a significantly lower tax rate in India is exhausting.

  • Exceptional charge of ₹161.7 crores incurred for Organon acquisition-related costs, with additional charges expected in subsequent quarters.

  • Emerging Markets formulations revenue growth slowed to 4.2% (USD311 million), impacted by geopolitical issues and difficult macroeconomic conditions.

Key financials

  1. Sales ₹15,183.6 Cr +10.1%YoY
  2. Gross Margin 80.5%
  3. EBITDA ₹4,417.7 Cr +2.7%YoY
  4. EBITDA Margin 28.9%
  5. Forex Gain ₹122 Cr
  6. Reported Net Profit After Tax ₹2,894.8 Cr
  7. Adjusted Net Profit ₹3,089.4 Cr
  8. EPS ₹12.1
  9. Exceptional Items (charge) ₹161.7 Cr
  10. Effective Tax Rate 27.8%
  11. R&D Investments ₹826.4 Cr
  12. R&D as % of Sales 5.4%

What they filed

Q1 FY27: revenue up 2.6%, net profit up 49.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue5,122 6,181 7,179 5,595 4,548 −11%5,688 −8%4,924 −31%5,741 +3%
EBITDA1,332 1,705 3,059 1,910 1,184 −11%1,759 +3%1,329 −57%1,964 +3%
Net profit838 1,156 2,042 745 564 −33%705 −39%609 −70%1,115 +50%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

SegmentSalesShare of Total Sales
Global Innovative Medicines351 Mn21.9%
India Formulations5,474.9 Mn36.1%
US Business427 Mn26.6%
Emerging Markets——
Rest of the World——

Capital allocation

high confidence
  • Debt Net $3.4 Bn
    Balance sheet of Sun continues to be strong with a net cash of $3.4 billion at the consolidated level.
  • M&A Organon Acquisition · Pending regulatory · Consideration ₹[object Object] (undisclosed)

    Exceptional charge of INR1,617 million towards Organon's acquisition-related costs. There would be additional charges on this account in the subsequent quarters.

    We have recently noted that Organon has received a shareholder approval for acquisition by Sun. The acquisition is subject to the satisfaction of remaining customary closing conditions and is on track to close by early 2027.

Guidance & targets

Revenue

  • Overall Top Line Growth Revenue · full year · High confidence high single-digit growth
    Think we should stick on to the high single-digit growth for the full year.

    — Jayashree Satagopan

Tax

  • Effective Tax Rate Tax · until Organon closing · High confidence similar range as in Q1 (27.8%)
    Going forward, and until Organon closing, we expect the tax rate to be in a similar range as in Q1.

    — Jayashree Satagopan

R&D

  • Annual R&D Spend R&D · annual · High confidence meet those numbers
    We have already guided for the annual number. And I think we should be able to meet those numbers.

    — Dilip Shanghvi

What to watch in Q2 FY27

Organon Acquisition Closing

Q4 FY27 (Jan-Mar 2027)
Current Shareholder approved, pending regulatory approvals
Target Acquisition completed

Why it matters

Significant M&A event that will impact future financials and strategic direction.

The acquisition is subject to the satisfaction of remaining customary closing conditions and is on track to close by early 2027.

Risks & concerns

  • US Generics Revenue Erosion

    medium

    US business sales declined 9.7% due to Lenalidomide erosion and additional competition in certain products.

    Management acknowledged

  • Increased Effective Tax Rate

    medium

    ETR increased to 27.8% from 24.3% in Q1 FY26, expected to remain in this range until Organon closing.

    Management acknowledged

  • Geopolitical and Macroeconomic Impact on Emerging Markets

    medium

    Emerging Markets revenue growth slowed to 4.2% due to geopolitical issues and difficult macroeconomic conditions.

    Management acknowledged

  • Organon Acquisition Costs

    medium

    ₹161.7 crores charged as exceptional item for acquisition-related costs, with more expected in subsequent quarters.

    Management acknowledged

Q&A highlights

6 direct
Deceleration of growth in specialty medicines Partial
I think our focus is on innovative business. And here, we would like the innovative business to continue to grow at a healthy rate. So we are expecting healthy growth to continue for innovative business in U.S., driven by new launches, as you know, Unloxcyt and Ilumya is also doing well. But we don't provide any product-wise revenue and growth at this moment. ... we do see seasonality with Levulan, our product for actinic keratosis. So as I had shared previously, we did see that seasonality this past quarter. We would expect to see similar next quarter.

Addresses a perceived slowdown in a key growth segment, attributing it partly to seasonality and partly to not disclosing product-wise data, while maintaining confidence in overall innovative business growth.

Asked by Amey Chalke

Sustainability of high gross margins Direct
As I was mentioning, we have seen a growth mainly driven by product mix. We've seen good growth in our branded generics business as well as our innovative medicines business. Both of these have resulted in a healthier margin profile for the quarter.

Clarifies the drivers of strong gross margins (product mix, branded generics, innovative medicines) and implies sustainability as these are strategic focus areas.

Asked by Damayanti Kerai

R&D spend variability and full-year outlook Direct
No, I think it's a time gap between what you call stopping some of the trials and starting some of the new indication trials. So I think don't look at the R&D spend this quarter. We have already guided for the annual number. And I think we should be able to meet those numbers.

Reassures investors that the lower R&D spend in Q1 is temporary and the company is on track to meet its annual R&D targets, indicating continued investment in pipeline.

Asked by Damayanti Kerai

Access and formulary coverage for new launches (Leqselvi & Unloxcyt) Direct
Maybe I'll start with Leqselvi because the access is different given the different kinds of products that we have. So from a payer access, which is what's most important for Leqselvi, we continue to grow. In fact, we added an important plan just this past quarter and improved the overall access. We do already for Leqselvi now have the majority of the covered lives available to us. Unloxcyt is a bit different because it's primarily administered in the health care setting. So there, we're very focused on formulary access at the cancer centers as well as the large integrated delivery networks within the U.S.

Provides insight into the commercialization strategy and progress for key specialty products, highlighting the different access pathways and positive traction.

Asked by Kunal Dhamesha

Progression of 'other expenses' and launch costs Partial
It's a bit of a misnomer to think there's a onetime expense on launch and then that expense goes away. It's a sustained investment to ensure you have a successful launch.

Clarifies that launch-related expenses for new products are not one-off but a sustained investment, impacting future expense lines and potentially margins.

Asked by Kunal Dhamesha

Sharp decline in US generic business revenues Direct
Yes. The largest part of the decline is Lenalidomide.

Identifies the primary cause of the US generics decline, which is a significant factor for the overall US business performance.

Asked by Neha Manpuria

Slowdown in Emerging Markets growth Direct
So, I think emerging markets, I would characterize the impact as a combination of both the geopolitical issues and difficult macroeconomic conditions in certain countries.

Explains external factors (geopolitics, macroeconomics) impacting a previously strong growth segment, indicating potential volatility.

Asked by Neha Manpuria

Rising employee costs relative to revenue growth Direct
There are two or three elements that actually impact the people cost or the salaries and comp and ben, right? One is the year-on-year increment that you get to see in the first quarter of every financial year... The second one is relating to additional field force that we had to employ, especially for our two new launches... The third one is also a bit of the forex impact that would also show as a higher cost this year.

Provides a detailed breakdown of the factors contributing to increased employee costs, offering transparency into operating expenses.

Asked by Surya Narayan Patra

2 min read 6 chapters

Detailed narrative

Strong Consolidated Revenue Growth Driven by India and Innovative Medicines

Sun Pharmaceutical Industries Limited reported consolidated sales of ₹15,183.6 crores for Q1 FY27, marking a 10.1% year-on-year growth. This performance was primarily fueled by robust growth in India formulations, which increased by 16% to ₹5,474.9 crores and contributed 36.1% to total sales. The Global Innovative Medicines segment also saw significant traction, with sales rising 12.8% to USD351 million, representing 21.9% of the company's total sales.

Gross Margin Expansion Despite US Generics Headwinds

The company achieved a gross margin of 80.5% in Q1 FY27, an improvement over the previous year, mainly attributed to a favorable product mix with higher contributions from branded generics and innovative medicines. However, the US business experienced a 9.7% decline in sales to USD427 million, largely due to Lenalidomide erosion and increased competition in certain generic products. This generic decline partially offset the growth in the innovative medicines portfolio.

Organon Acquisition Progress and Associated Costs

The acquisition of Organon is progressing, having received shareholder approval and is on track to close by early 2027, specifically in Q4 FY27. The company incurred an exceptional charge of ₹161.7 crores in Q1 FY27 related to acquisition costs, with further charges anticipated in subsequent quarters. An integration management office has been established to prepare for the day-one transition.

Strategic Focus on Semaglutide and R&D Investments

Sun Pharma has become the second-largest generic semaglutide injectable player in India, being the sole provider of the auto-injector format. The company has also secured approvals for generic semaglutide in Brazil and South Africa, with launches underway or imminent. Consolidated R&D investments for the quarter stood at ₹826.4 crores, representing 5.4% of sales, with 30% allocated to innovative R&D, demonstrating a continued commitment to pipeline development.

Emerging Markets Face Geopolitical and Macroeconomic Challenges

Emerging Markets formulations revenue grew by 4.2% to USD311 million, contributing 19.4% to total consolidated revenue. This growth rate was lower than previous quarters, attributed by management to a combination of geopolitical issues and difficult macroeconomic conditions in various countries. The company is focusing on ensuring product availability and optimal launch execution in these markets.

Factors Influencing Operating Expenses and Tax Rate

The company's operating expenses, particularly employee costs, saw an increase due to annual increments, additional field force deployment for new product launches (Leqselvi and Unloxcyt), and foreign exchange impacts. Management clarified that launch-related expenses are a sustained investment rather than a one-time cost. The effective tax rate for the quarter rose to 27.8% from 24.3% in Q1 FY26, as the benefits from a lower tax rate in India are gradually exhausting, and this rate is expected to persist until the Organon acquisition closes.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls